For the quarter ending 2025-09-30, INAB had -$2,535K decrease in cash & cash equivalents over the period. -$3,524K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -3,854 | -10,644 |
| Depreciation and amortization | 244 | 511 |
| Non-cash stock-based compensation | 692 | 1,786 |
| Amortization of financing lease right-of-use assets | 126 | 526 |
| Amortization of operating lease right-of-use assets | 157 | 416 |
| Loss on disposal of construction in progres | 0 | - |
| Prepaid expenses and other current assets | 564 | -943 |
| Other non-current assets | -106 | 0 |
| Accounts payable | -175 | -10 |
| Accrued expenses and other current liabilities | -217 | -412 |
| Short-term operating lease liabilities | 201 | 225 |
| Long-term operating lease liabilities | -240 | -390 |
| Net cash used in operating activities | -3,524 | -7,049 |
| Purchases of property and equipment | 0 | 0 |
| Construction in progress | 0 | 0 |
| Net cash used in investing activities | 0 | 0 |
| Payment of issuance costs from december 2023 issuance of common stock | 0 | 0 |
| Proceeds from the issuance of common stock, net of issuance costs | 1,112 | 7,352 |
| Proceeds from the exercise of series c warrants, net of issuance costs-Series ABWarrants | 0 | 1,884 |
| Proceeds from the exercise of series c warrants, net of issuance costs-Series CWarrants | 0 | 383 |
| Principal payments on financing leases | 123 | 459 |
| Net cash provided by financing activities | 989 | 9,160 |
| Net (decrease) in cash and restricted cash | -2,535 | 2,111 |
| Cash and cash equivalents at beginning of period | 11,386 | - |
| Cash and cash equivalents at end of period | 10,962 | - |
IN8BIO, INC. (INAB)
IN8BIO, INC. (INAB)